Elizabeth Dudnik

Head of the Lung Cancer Service, Assuta Medical Centers, Chair of the Israeli Lung Cancer Group #ILCG #ISCORT

[Patrick Forde @FordePatrick]

Excellent presentation by @DrMarkAwad of exploratory neoadj nivo-ipi arm vs chemo of #cm816. Improved pCR, EFS and trend toward improved OS. Striking early crossing of EFS curves suggests chemo is still needed in this setting.

[Stephen V Liu, MD @StephenVLiu]

#ESMO23 Dr. @DoctorJSpicer presents OS data from KEYNOTE 671: neoadjuvant pembrolizumab + chemotherapy followed by surgery and adjuvant pembro x 1 year. Perioperative IO improves survival. OS HR 0.72, 3y OS rate 71% vs 64%, impressive tails. Now an FDA approved standard.

[Stephen V Liu, MD @StephenVLiu]

#ESMO23 RR 63% with pembrolizumab + adagrasib in PDL1 high NSCLC. Median time to response 1.4m. mDOR and mPFS not yet reached. Single arm study but recall RR with pembro in KEYNOTE 024 was 44.8%. Certainly warrants a phase III study.

[Stephen V Liu, MD @StephenVLiu]

#ESMO23 Included 54 pts with PD-L1 high NSCLC. Balanced arms. Only 6% discontinuation of adagrasib from TRAEs. Treatment related hepatic events in < 10% of adagrasib + pembrolizumab arm. Very reassuring. Why different from sotorasib? PK difference? Binding differences?

[Jarushka Naidoo @DrJNaidoo]

#WCLC23 Presidential Session🔥

Incredible presentation by Erik Lim 🇬🇧 of the Ph III MARS2 trial of Surgery v No surgery in mesothelioma:
- no OS benefit
- poorer QOL
- higher toxicity

Critical study. Congrats to all authors @iaslc @OncoAlert #LCSM

[Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ @APassaroMD]

🚨#WCLC23 Ph3 #FLAURA2
Primary endpoint: 𝐏𝐅𝐒 𝐛𝐲 𝐢𝐧𝐯
▪️PFS:Osi+chemo 𝘷𝘴. Osi: 25.5 𝘷𝘴. 16.7
HR 0.62; p<0.0001; 51% maturity
▪️OS was immature (27%)
HR 0.90; p=0.52
▪️G ≥3 AEs: 64%/27%

A positive study to integrate w/ many Ph3 trials ready to be out in this field

[Yüksel Ürün @DrYukselUrun]

🌟 Combining Stereotactic Ablative Radiotherapy (SABR) with immunotherapy (I-SABR) shows a significant boost in 4-year event-free survival rates, compared to SABR alone.
🔘Fewer relapses, promising safety profile, and a potential game-changer for patients with early-stage NSCLC.
🔘Awaiting further results from ongoing trials for confirmation. 🎗️💊
@TheLancet @OncoAlert @OncBrothers @IASLC
#lungcancer #Immunotherapy

[Stephen V Liu, MD @StephenVLiu]

Phase III IPSOS trial @TheLancet: first-line atezolizumab (anti-PDL1) monotherapy to single agent chemotherapy in 453 pts ineligible for platinum-doublet (PS 2-3 or age plus comorbidities). QoL and survival favored atezolizumab (HR 0.78, 2y OS 24% vs 12%).
https://t.co/jkE1bSEJbY

[Brad Loncar @bradloncar]

Astra and Daiichi say that their TROP2 ADC hit on PFS at interim in the anticipated phase 3 NSCLC trial but that OS needs to mature further. No data provided today. https://t.co/JlVKG6E98T

[Patrick Forde @FordePatrick]

First snapshots of Aegean data, periadjuvant phase 3 trial in resectable lung cancer. Neoadjuvant chemo-Durva then surgery then adj Durva vs neoadj chemo alone then surgery. Looking forward to digging into these data! Does adj year of PD-L1 blockade add to neoadj alone? #LCSM

[Charles Swanton @CharlesSwanton]

Not enough attention has been paid to chronic fatigue and out of hours working amongst health professionals and its impact on their safety and of others- these data do not surprise me - I have heard many stories over 25yrs of fatal accidents likely resulting from night work

[Charles Swanton @CharlesSwanton]

Altogether, this suggests a mechanistic and causative link between air pollutants triggering expansion of pre-existing mutant cells in normal tissues via a clinically actionable inflammatory axis. (Thanks @Biorender)

[Charles Swanton @CharlesSwanton]

Tumour promotion was first proposed by Berenblum & Shubik and developed by Allan Balmain and others. Thank you to Prof Balmain for this excellent N&V https://t.co/WasMLTsrA1

[Charles Swanton @CharlesSwanton]

Today our important study on air pollutants in the promotion of lung cancer has been published in @Nature led by @WillHilliam @LimEmilia @DrClareWeeden @SwantonLab ...Thread below🧵https://t.co/q1ICykmVox

[CancerCareHomes @CancerCareHomes]

Amivantamab in EGFR exon20 insertion in Non-small cell lung cancer #NSCLC #lungcancer #ELCC23

[Jarushka Naidoo @DrJNaidoo]

#ELCC23

3-yr Update of CM816 trial: Neoadj chemoIO v chemo shows
- contd EFS benefit
- OS HR 0.67 (p=0.012)
- *chemoIO appears to protect against CNS progression* - this is the gold

Impressive data. Identifying what further IO adds, is the key quesn

@myESMO @FordePatrick #LCSM

[Jordi Remon @JordiRemon]

CM816 trial 👑: Neoadjuvant chemo + IO improved 3-year EFS vs neoadj Ch alone with lowe 🧠 recurrences with chemoIO approach💡Challenges: Do we need ADJ IO after the neoadj CT+IO approach?Role of this strategy in stage I/II NSCLC? In stage III: CM816 vs PACIFIC? @myESMO #ELCC2023

[KLI für Lungenforschung und pneumolog. Onkologie @lungenforschung]

Die dazugehörige Publikation in Zusammenarbeit mit @AurelieSwalduz @Alfdoc2 @lungendoc @hausruck1
@_SayedHashemi @ElizabethDudnik @lungcancerpall @JairBar4
@ZerAlona und anderen finden Sie unter https://t.co/wVdhCYj0KB

[Elizabeth Dudnik @ElizabethDudnik]

@AMalfettonePhD @MLJohnsonMD2 @OncoAlert @myESMO Indeed, the superiority confirmed. ORR and the lack of OS benefit considering the low cross-over rate is a bit disappointing though..@myESMO

[Elizabeth Dudnik @ElizabethDudnik]

IPSOS: a very important ph 3 randomized study confirming superiority of 1L Atezo over SA Chemo in ECOG PS 2/3 elderly aNSCLC pts- irrespectively of PD-L1 status! New standard for this poor prognosis subset. Congratulations to authors!
⁦@myESMO⁩ #ESMO22